{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T14:41:58Z","timestamp":1788532918868,"version":"build-2803163510"},"reference-count":19,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,4,11]],"date-time":"2017-04-11T00:00:00Z","timestamp":1491868800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["mcpiqojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings: Innovations, Quality & Outcomes"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.mayocpiqo.2017.04.003","type":"journal-article","created":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T03:23:10Z","timestamp":1498188190000},"page":"111-116","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["A Rare STRN-ALK Fusion in Lung Adenocarcinoma Identified Using Next-Generation Sequencing\u2013Based Circulating Tumor DNA Profiling Exhibits Excellent Response to Crizotinib"],"prefix":"10.1016","volume":"1","author":[{"given":"Yan","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Kui","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Mei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zong-Yu","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.mayocpiqo.2017.04.003_bib1","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1634\/theoncologist.2014-0241","article-title":"FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements","volume":"19","author":"Kazandjian","year":"2014","journal-title":"Oncologist"},{"issue":"7153","key":"10.1016\/j.mayocpiqo.2017.04.003_bib2","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature05945","article-title":"Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer","volume":"448","author":"Soda","year":"2007","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.mayocpiqo.2017.04.003_bib3","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1158\/1078-0432.CCR-14-2791","article-title":"Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for\u00a0precision cancer medicine","volume":"21","author":"Katayama","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.mayocpiqo.2017.04.003_bib4","series-title":"AJCC Cancer Staging Manual","author":"Edge","year":"2011"},{"issue":"5","key":"10.1016\/j.mayocpiqo.2017.04.003_bib5","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nm.3519","article-title":"An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage","volume":"20","author":"Newman","year":"2014","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.mayocpiqo.2017.04.003_bib6","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1001\/jamaoncol.2016.0173","article-title":"Prospective validation of rapid plasma genotyping for the detection of EGFR and KRAS mutations in advanced lung cancer","volume":"2","author":"Sacher","year":"2016","journal-title":"JAMA Oncol"},{"issue":"13","key":"10.1016\/j.mayocpiqo.2017.04.003_bib7","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1158\/1078-0432.CCR-08-0168","article-title":"EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer","volume":"14","author":"Koivunen","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.mayocpiqo.2017.04.003_bib8","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.lungcan.2014.02.007","article-title":"ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features","volume":"84","author":"Pan","year":"2014","journal-title":"Lung Cancer"},{"issue":"26","key":"10.1016\/j.mayocpiqo.2017.04.003_bib9","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1200\/JCO.2009.22.6993","article-title":"Clinical features\u00a0and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK","volume":"27","author":"Shaw","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"15","key":"10.1016\/j.mayocpiqo.2017.04.003_bib10","doi-asserted-by":"crossref","first-page":"4273","DOI":"10.1158\/1078-0432.CCR-13-0318","article-title":"ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer","volume":"19","author":"Gainor","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2017.04.003_bib11","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/JTO.0b013e3182370e30","article-title":"EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR","volume":"7","author":"Wu","year":"2012","journal-title":"J\u00a0Thorac Oncol"},{"issue":"3","key":"10.1016\/j.mayocpiqo.2017.04.003_bib12","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/path.4209","article-title":"Identification of\u00a0recurrent FGFR3 fusion genes in lung cancer through\u00a0kinome-centred RNA sequencing","volume":"230","author":"Majewski","year":"2013","journal-title":"J\u00a0Pathol"},{"issue":"11","key":"10.1016\/j.mayocpiqo.2017.04.003_bib13","doi-asserted-by":"crossref","first-page":"4233","DOI":"10.1073\/pnas.1321937111","article-title":"Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer","volume":"111","author":"Kelly","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2017.04.003_bib14","doi-asserted-by":"crossref","first-page":"e87170","DOI":"10.1371\/journal.pone.0087170","article-title":"Identification of a recurrent STRN\/ALK fusion in thyroid carcinomas","volume":"9","author":"Perot","year":"2014","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.mayocpiqo.2017.04.003_bib15","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1097\/PAS.0000000000000610","article-title":"Two cases of renal cell carcinoma harboring a novel STRN-ALK fusion gene","volume":"40","author":"Kusano","year":"2016","journal-title":"Am J Surg Pathol"},{"issue":"15","key":"10.1016\/j.mayocpiqo.2017.04.003_bib16","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.1158\/1078-0432.CCR-15-3000","article-title":"Oncogenic ALK fusion in rare and aggressive subtype of colorectal adenocarcinoma as a potential therapeutic target","volume":"22","author":"Yakirevich","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"23","key":"10.1016\/j.mayocpiqo.2017.04.003_bib17","doi-asserted-by":"crossref","first-page":"7394","DOI":"10.1158\/1078-0432.CCR-11-1648","article-title":"ALK mutations conferring differential resistance to structurally diverse ALK inhibitors","volume":"17","author":"Heuckmann","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"17","key":"10.1016\/j.mayocpiqo.2017.04.003_bib18","doi-asserted-by":"crossref","first-page":"4682","DOI":"10.1158\/1078-0432.CCR-11-3260","article-title":"Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants","volume":"18","author":"Heuckmann","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"20","key":"10.1016\/j.mayocpiqo.2017.04.003_bib19","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1200\/JCO.2013.49.6596","article-title":"Remarkable response to crizotinib in woman with anaplastic lymphoma kinase-rearranged anaplastic thyroid carcinoma","volume":"33","author":"Godbert","year":"2015","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Mayo Clinic Proceedings: Innovations, Quality & Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2542454817300061?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2542454817300061?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T14:07:27Z","timestamp":1762870047000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2542454817300061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S2542454817300061"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocpiqo.2017.04.003","relation":{},"ISSN":["2542-4548"],"issn-type":[{"value":"2542-4548","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Rare STRN-ALK Fusion in Lung Adenocarcinoma Identified Using Next-Generation Sequencing\u2013Based Circulating Tumor DNA Profiling Exhibits Excellent Response to Crizotinib","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings: Innovations, Quality & Outcomes","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocpiqo.2017.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}